Cain Brothers Newsletters: Industry Insights
“Industry Insights” is a bi-weekly email newsletter published by Cain Brothers, a division of KeyBanc Capital Markets. The newsletter features innovative and original perspectives about healthcare services, healthcare IT, and life sciences from our team of experienced investment bankers. Read the latest newsletter content below, and subscribe to start receiving the newsletter in your inbox.
Longevity Clinics: Wellness Trend or Investable Asset Class?
February 5, 2026 – Banker Commentary by Joe Baggett
The Rise of Health Optimization
The longevity movement has gone mainstream. Fueled by the likes of Andrew Huberman and Bryan Johnson, health optimization for extending lifespan and healthspan has moved from impassioned niche circles to broader consumer preferences. According to McKinsey’s Future of Wellness report, more than 82% of U.S. consumers now consider wellness a top or important priority in their everyday lives, and 60% consider healthy aging/longevity very or extremely important.
The longevity market reached approximately $23 billion in 2025, and is projected to hit $63 billion by 2035, with capital flowing into biotech, supplements, diagnostics, and patient-facing clinics. Within the longevity clinic space, the boundaries between concierge medicine, aesthetics, and longevity services remain blurred, but the underlying growth is undeniable.
Private Equity Activity Signals Market Maturation
While VCs dominated early-stage longevity biotech, recent PE activity in patient-facing clinics signals the sector is maturing. Approximately 800 longevity-focused clinics now operate across the United States. The concierge medicine market, which overlaps significantly with longevity clinics, is projected to reach $48 billion by 2033, from $20 billion in 2024, representing a 10% CAGR.
Recent Relevant PE Transactions:
- Revelstoke Capital Partners’ investment in Griffin Concierge Medical (September 2025), a Tampa-based concierge primary care group offering preventive screenings, hormone optimization, weight management, and longevity services
- Brightstar Capital Partners’ acquisition of Analyte Health (August 2025), a Houston-based direct-to-consumer digital health company offering clinical testing, virtual care, and prescription fulfillment across wellness and hormonal therapy categories
- Boyne Capital and Platt Park Capital’s investment in Novellum Longevity (July 2025), an MSO for longevity and functional wellness clinics formed through the acquisition of ThriveMD's non-clinical assets, offering hormone replacement, peptide therapy, diagnostics, and regenerative medicine
- Shore Capital Partners’ platform launch of Agentis Longevity (December 2024), a Nashville-based longevity healthcare platform offering hormone optimization, health testing, weight management, peptides, and stem cell therapies
Recent Relevant VC Funding Rounds:
- Fountain Life, brick-and-mortar longevity centers in major metros with $10,000–$21,000 annual memberships for early-detection diagnostics and optimization protocols; $18 million Series B, $150 million total raised (August 2025)
- Function Health, consumer diagnostics platform offering 160+ laboratory tests via Quest Diagnostics partnership, plus MRI scanning through the Ezra acquisition; $300 million Series B at $2.5 billion valuation (May 2025)
- Prenuvo, whole-body MRI screening company with 17 clinics across North America, 110,000+ members, expanding to Europe and Australia; $120 million Series B at $600 million valuation (February 2025)
The Cash-Pay Model: Opportunity and Constraint
Longevity clinics depend almost entirely on out-of-pocket spending. Annual memberships typically start at $3,000+, with initial evaluations costing $1,000 to $25,000. Clinics avoid administrative burden and margin compression from insurance negotiations, generating predictable revenue from affluent customers with high retention rates. However, the addressable market remains limited to high-income individuals. Without insurance reimbursement, democratization requires demonstrating cost savings through reduced downstream utilization, a thesis that gains traction as clinics generate longitudinal data showing measurable improvements in cardiovascular risk, metabolic markers, and early cancer detection.
For investors, the strategic question is whether to build scale in the current high-margin cash-pay environment or position for reimbursement expansion that could increase market size while compressing margins.
A Similar Bottleneck: Provider Recruitment
A central challenge in longevity clinic growth is physician supply. The model requires physicians who want out of traditional practice and can attract and retain an affluent patient base, which is a narrow group that limits organic growth. Virtual care models offer a potential release valve, enabling physicians to manage larger patient panels across geographies without brick-and-mortar constraints. However, the trade-off is potentially brand stickiness: high-touch, in-person relationships drive the retention rates that make these businesses attractive, and virtualization risks commoditizing the patient experience.
The consolidators who win will leverage technology to optimize physician time through technology-driven personalization, longitudinal biomarker tracking, and standardized protocols. Equally important, platforms that accumulate outcomes data demonstrating measurable health improvements build both clinical credibility and barriers to entry. In a sector where marketing hype often outpaces science, defensible data becomes a differentiator.
Investment Outlook
For PE, the opportunity lies in professionalizing a fragmented and nascent sector. The growth playbook is familiar: acquire or build clinics with proven unit economics and physician leadership, implement standardized protocols, invest in technology for personalization at scale, and build national brands.
Even with shifting consumer preferences, we are still early. Unlike traditional healthcare subspecialties, longevity has an elastic demand curve. The addressable market isn’t fixed to specific disease prevalence. Investment in direct-to-consumer education and marketing doesn't just capture existing demand, it expands the total addressable market.
The cash-pay model has underappreciated advantages. Consumers prefer transparency and the delta between out-of-pocket costs and what patients pay through insurance is often smaller than perceived, and the enhanced care experience justifies the premium. If early detection and prevention reduce downstream medical costs, the investment pays for itself.
Longevity clinics are moving from trend to infrastructure. The winners will be those who prove outcomes, scale talent, and own the relationship with the affluent, health-conscious consumer.
Archives
See our monthly industry insights below:
